These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Estey E; Keating MJ; Plunkett W; McCredie KB; Freireich EJ Semin Oncol; 1987 Jun; 14(2 Suppl 1):58-63. PubMed ID: 3473684 [No Abstract] [Full Text] [Related]
3. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. Heinemann V; Jehn U Leukemia; 1990 Nov; 4(11):790-6. PubMed ID: 2232893 [No Abstract] [Full Text] [Related]
4. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Estey EH; Plunkett W; Kantarjian H; Rios MB; Keating MJ Leuk Lymphoma; 1993; 10 Suppl():115-21. PubMed ID: 8481661 [No Abstract] [Full Text] [Related]
5. Biochemical and cellular pharmacology of cytosine arabinoside. Kufe DW; Spriggs DR Semin Oncol; 1985 Jun; 12(2 Suppl 3):34-48. PubMed ID: 3925560 [No Abstract] [Full Text] [Related]
6. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy. Harris AL; Grahame-Smith DG; Potter CG; Bunch C Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687 [TBL] [Abstract][Full Text] [Related]
7. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935 [No Abstract] [Full Text] [Related]
8. Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells. Riva-Lavieille C; Ressayre C; Barra Y; Carcassonne Y; Iliadis A Ther Drug Monit; 1994 Aug; 16(4):375-9. PubMed ID: 7974627 [TBL] [Abstract][Full Text] [Related]
9. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322 [TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine arabinoside: advances in clinical pharmacology and therapeutic results. Woodruff RK; Wiley JS Aust N Z J Med; 1983 Dec; 13(6):561-3. PubMed ID: 6586146 [No Abstract] [Full Text] [Related]
12. [Cytosine arabinoside as a polyvalent drug in the treatment of acute non-lymphoid leukemias]. Sánchez Fayos J Sangre (Barc); 1986; 31(5):566-73. PubMed ID: 3810411 [No Abstract] [Full Text] [Related]
14. Studies on the cytotoxicity of cytosine arabinoside. Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698 [No Abstract] [Full Text] [Related]
15. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Roberts JD; Ershler WB; Tindle BH; Stewart JA Cancer; 1985 Sep; 56(5):1001-5. PubMed ID: 3860278 [TBL] [Abstract][Full Text] [Related]
16. Prediction of therapeutic response in acute myelocytic leukemia. Preisler HD; Rustum YM Haematol Blood Transfus; 1979; 23():93-8. PubMed ID: 296118 [No Abstract] [Full Text] [Related]
17. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). Riva CM; Rustum YM; Preisler HD Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925 [No Abstract] [Full Text] [Related]
18. A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Momparler RL Cancer Res; 1974 Aug; 34(8):1775-87. PubMed ID: 4526298 [No Abstract] [Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report. Grant S; Baker M; Bhalla K Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]